Академический Документы
Профессиональный Документы
Культура Документы
16-Dec-16
Market
Market
Morning Traded Market
KEY LEVELS
-0.28%
19327
0.50%
21,980.00
-0.36%
Sensex
Nifty
26,519.07
8,153.60
-0.31%
-0.35%
DOW
NASDAQ
19,792.85
5,456.86
-0.60%
0.37%
CAC
4,819.23
1.04%
DAX
11,366.40
1.07%
FTSE
EW ALL SHARE
6,999.01
14,710.17
0.71%
-0.05%
HANG SENG
Market Outlook
Persistent : 9:30 AM
8,158.00
NIKKIE
Resistance 1: 8310
Resistance 2: 8598
Concall
% Change
SGX NIFTY
Support 1 : 8056
Support 2 : 7916
Event Today
Value
% Change in 1 day
Value
% Change
27019.00
-2.06%
39295.00
-5.08%
54.49
-1.96%
234.20
0.89%
67.83
0.59%
0.04%
-0.28%
CRUDEOIL
NATURALGAS
DOLLAR/RS.
EURO/RS.
POUND/RS.
70.67
84.10
% Change in 1 day
Institutional Turnover
FII
Investor
Buy(Cr.)
Sale(Cr.)
Net(Cr.)
3781
4393
(612)
32430
34362
(1932)
2016
1012696
1011778
918
Investor
Buy(Cr.)
Sale(Cr.)
Net(Cr.)
1989
13501
2167
13473
(177)
29
468525
440180
28345
15-Dec-16
Dec-16
DII
15-Dec-16
Dec-16
2016
Quote of the Day : "By confining himself to a relatively few, easy-to-understand cases, a reasonably intelligent,
informed and diligent person can judge investment risks with a useful degree of accuracy."
Benjamin Graham
IEA Snapshot
HDFC Bank is one of the leading banks in the industry with the strong fundamentals, best in assets quality, adequate capital, steady loan
growth and consistency in profitability growth. Where some of its peers in large cap are struggling with the deteriorating assets quality,
HDFC Bank is well poised to take the advantage from improving macroeconomic scenario. While in the short term there may be hiccups in
the lending activity due to demonetization drive and this has led to uncertainty over the earnings during this period, but the long term
growth and profitability remain intact for the bank. One of the huge benefits from the demonetization drive will arise in the form of shoot
in CASA ratio which will help the bank to cut the rates further to drive the demand. Strategy of the management to focus on high yield
products will help the bank to maintain the NIMs apart from the expected benefits from spurt in CASA (due to demonetization). We expect
the RoE of 19% and maintain BUY rating on this stock with our previous target price of Rs 1400.
GODREJCP
"BUY"
Management is rationalizing ad expenses and has increased home insecticide products prices by 2% in the late September 2016 to counter
upward movement of input prices. Going forward we expect relatively less impact on GODREJCP compared to other FMCG players, as
company gets approx 46% of its revenue from international market. Secondly companys proactive initiatives of cutting promotions and
increasing price of the products gives us confidence on margin side. Considering lesser dependence of company in Indian business,
proactive approach towards maintaining the margin and relatively less penetrated product portfolio, we have positive view on this stock
and we maintain `BUY with target price of Rs 1760.
*For details, refer to our daily report- India Equity Analytics
Top News
Mgt Int : BAJAJAUTO
Dominar price logical; may not impact Enfield volumes: Bajaj
>>Bajaj launches new Dominar 400, goes after Royal Enfield
>>Mgt is very upbeat on increasing market share with the
launch of the new 400cc bike Dominar. Mgt is confident of
selling 2 lakh bikes per year.
>>Bajaj is hopeful of clocking sales growth in January-March
2107 and expects to do better than the industry on back of new
launches and product mix.
Sunpharma
The US Department of Justice accused two former generic
pharmaceutical executives of colluding with other generic
manufacturers to fix prices, the first criminal charges stemming from a
two-year investigation.
The executives, Jeffrey Glazer and Jason Malek, were charged in
Philadelphia with conspiring to fix the prices of an antibiotic,
doxycycline hyclate, and to split up the market for glyburide, a diabetes
drug as per the US Department.
Other companies in the congressional probe have since publicly
disclosed receiving subpoenas, including Mylan NV, Allergan, which
later sold its generics business to Teva, Lannett Co, Impax Laboratories,
Par Pharmaceuticals, which is owned by Endo Pharmaceuticals, Sun
Pharmaceutical Industries,Taro Pharmaceuticals Ltd and Mayne, which
purchased a portfolio of drugs from Allergan and Teva.
U.K. retail sales rose to 0.2%, from 1.8% in the preceding month
whose figure was revised down from 1.9%. Analysts had expected retail
sales to rise 0.2% last month.
Euro Zone Services PMI fell to 53.1, from 53.8 in the preceding
quarter. Analysts had expected Euro Zone Services PMI to remain
unchanged at 53.8 in the last quarter.
Swedish Unemployment Rate fell to 6.2%, from 6.4% in the preceding
month. Analysts had expected Swedish Unemployment Rate to fall to
6.3% last month.
U.K. claimant count change rose to a seasonally adjusted 2.4K, from
13.3K in the preceding month whose figure was revised up from 9.8K.
Individual
Foreign Institutions
Nifty Movers
TRADING IDEAS
Scrip
Reco
RBLBANK
Buy
BIOCON Dec.
900 PE
Short
(1 lot =
1100)
Initiation Price
355.7
6.55
Target 1
379
404
0.5
Rational
330
10
Country
US
UK/EURO ZONE
INDIA
Monday
12th Dec 16
Economic Calendar
Tuesday
Wednesday
13th Dec 16
14th Dec 16
Thursday
15th Dec 16
Friday
16th Dec 16
Building Permits ,
Housing Starts.
IIP
WPI
Risk Disclosure & Disclaimer: This report/message is for the personal information of
the authorized recipient and does not construe to be any investment, legal or taxation
advice to you. Narnolia Securities Ltd. (Hereinafter referred as NSL) is not soliciting any
action based upon it. This report/message is not for public distribution and has been
furnished to you solely for your information and should not be reproduced or
redistributed to any other person in any from. The report/message is based upon publicly
available information, findings of our research wing East wind & information that we
consider reliable, but we do not represent that it is accurate or complete and we do not
provide any express or implied warranty of any kind, and also these are subject to change
without notice. The recipients of this report should rely on their own investigations,
should use their own judgment for taking any investment decisions keeping in mind that
past performance is not necessarily a guide to future performance & that the the value of
any investment or income are subject to market and other risks. Further it will be safe to
assume that NSL and /or its Group or associate Companies, their Directors, affiliates
and/or employees may have interests/ positions, financial or otherwise, individually or
otherwise in the recommended/mentioned securities/mutual funds/ model funds and
other investment products which may be added or disposed including & other mentioned
in this report/message.